sing the Right Dose of Gefitinib medicine for Better Treatment in Lung Cancer
Not Applicable
- Conditions
- Health Condition 1: C343- Malignant neoplasm of lower lobe,bronchus or lungHealth Condition 2: C340- Malignant neoplasm of main bronchusHealth Condition 3: C342- Malignant neoplasm of middle lobe,bronchus or lungHealth Condition 4: C348- Malignant neoplasm of overlappingsites of bronchus and lungHealth Condition 5: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungHealth Condition 6: C341- Malignant neoplasm of upper lobe,bronchus or lung
- Registration Number
- CTRI/2024/01/061126
- Lead Sponsor
- Intramural Funding, MAHE, Manipal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Non-Small Cell Lung Cancer patients (both males and females) with EGFR positive mutation.
2. Age group of 18-80 years.
3. Patients who are willing to give informed consent.
Exclusion Criteria
1. HIV positive patients.
2. Patients with seriously ill conditions (eg: COVID 19 etc.,) or clinically unstable patients.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The current research aims to develop an appropriate gefitinib population pharmacokinetic model for deriving an individualized gefitinib dosing strategy for NSCLC patients in tertiary care hospitals.Timepoint: 3 years
- Secondary Outcome Measures
Name Time Method Development of such a Population pharmacokinetic model for gefitinib will aid in the implementation of precision therapy for the management of NSCLC. Thus, this study would comprehensively analyse precision therapy of lung cancer patients in our settings.Timepoint: 3 years